Telehealth company Hims & Hers dropped its plan to offer a knockoff version of the weight-loss pill Wegovy on Saturday — two ...

Hims & Hers said it would stop selling its new compounded semaglutide pill after "constructive conversations with ...

Following threats from the Food and Drug Administration (FDA) that it would take "decisive" action against companies selling "illegal copycat drugs," telehealth company Hims & Hers announced it would ...

Federal officials had warned that the new product from the online provider of weight loss drugs might be illegal.

By Anusha Shah and Amina Niasse Feb 7 (Reuters) - Online telehealth company Hims & Hers on Saturday reversed course on its ...

By Carlos Méndez and Chris Thomas Feb 5 (Reuters) - The U.S. Food and Drug Administration (FDA) will take swift action ...

Hims & Hers Health Inc. announced it will stop selling a copycat version of Novo Nordisk's Wegovy weight-loss pill two days ...

By Maggie Fick and Bhanvi Satija LONDON, Feb 6 (Reuters) - Hims & Hers' gambit to sell a $49 compounded version of Novo ...

Hims Hers Health announced on Saturday that it will stop offering access to its compounded semaglutide pill following a ...

At a starting cost of just $49 per month, the new pills are the cheapest GLP-1 option yet. But experts say compounded drugs ...

By Amina Niasse NEW YORK, Feb 7 (Reuters) - Companies looking to sell weight-loss drugs directly to consumers, including Novo ...

Your parents, your doctor, your spouse, or even your adult children constantly nag you: “Did you take your medicine? Did you ...